SUMMARY ANSWER: The RBMY1 functional copy dosage is positively correlated with sperm motility, and dosage insufficiency is an independent risk factor for asthenozoospermia.
Introduction
On the Y-chromosome, azoospermia factor (AZF) region-linked genes play crucial roles in maintaining the sperm quality and quantity required for male fertility (Kamp et al., 2000; Kuroda-Kawaguchi et al., 2001; Repping et al., 2002 Repping et al., , 2003 Rozen et al., 2012; Krausz et al., 2014) . Among these genes, RBMY1, encoding the RNA-binding motif protein, Y-chromosome, family 1, is notable, since the gene, as one of the remaining four ancestral genes on the Y-chromosome, has developed a multiple-copy condition on the modern human Y-chromosome (Livernois et al., 2012) , presenting a distinct evolutionary direction in contrast with most of the primitive Y-chromosome-linked genes, which show decay (Bellott et al., 2014) . The retention and amplification of the RBMY1 with restricted expression in the adult testis imply that it may contribute to male-specific physiological processes such as spermatogenesis (Tyler-Smith, 2008) . Deficiency in mouse Rbmy1 can cause spermatogenic arrest (Mahadevaiah et al., 1998) , further suggesting that RBMY1 may be an important candidate for spermatogenic impairment and male infertility.
However, the effect of RBMY1 on spermatogenic phenotypes has not been determined, mainly because (i) there are at least 30 homologous loci with high sequence similarity to the six functional copies of RBMY1 located in the AZFb region (Chai et al., 1997; Elliott et al., 1997) , which interferes with the study of the genomic organization of its functional copy cluster and (ii) several AZF structural mutations that are responsible for spermatogenesis failure remove all or partial copies of RBMY1 while simultaneously involving other AZF genes (Repping et al., 2002; Jobling, 2008) , leading to difficulty in evaluating the contribution of RBMY1 to spermatogenesis failure as well as male infertility.
The Y-chromosome exhibits the most copy number variations (CNVs) of all the human chromosomes . This condition is particularly prominent in the AZF region, largely due to frequent non-allelic homologous recombination (NAHR) (Blanco et al., 2000; Kamp et al., 2000; Kuroda-Kawaguchi et al., 2001; Repping et al., 2002) . Therefore, it can be expected that some local NAHRmediated deletions or duplications in the AZFb region have caused variation in the number of functional RBMY1 copies with limited disturbance of other AZF genes. If so, investigating the association of such CNVs with spermatogenic phenotypes will be helpful in understanding the potential role of RBMY1 in spermatogenesis (Freeman et al., 2006) .
In the present study, we detected the number of functional RBMY1 copies in 486 fertile males and 1070 Y-chromosome haplogroup (Y-hg) O3e or O3 * carriers with normal karyotypes and the absence of known AZF structural mutations responsible for spermatogenesis failure. The association of RBMY1 CNV with semen parameters was analysed in 564 men with oligozoospermia and/or asthenozoospermia and 506 with normozoospermia. With this work, the Y-hgindependent CNV in RBMY1 was identified, and a significant association between the CNV and sperm motility was observed. Further evidence from the study population suggested that RBMY1 could be a candidate for asthenozoospermia; this was supported by the positive correlation between RBMY1 copy dosage and its mRNA/protein level in the testis and between sperm RBMY1 protein level and motility as well as the concentrated distribution of the RBMY1 protein in the neck and mid-piece region of sperm as well as the principal piece of the sperm tail. (Cooper et al., 2010) . All of the patients and controls underwent a minimum of two semen analyses. Patients were excluded upon identification of any significant androgenic or endocrine abnormalities in a physical examination, hormone analysis and scrotal ultrasound, including hypogonadotropic hypogonadism, cryptorchidism, varicocele, seminal ductal obstruction, testicular trauma and tumour. The patients determined to have chromosomal aberration through karyotype testing were also excluded. In addition, 18 semen samples from males seeing a doctor due to couple infertility and 15 testis biopsy samples presenting normozoospermia from males with obstructive azoospermia were collected.
Materials and Methods

Study population
Ethical approval
The study was approved by the Ethical Review Board of West China Hospital, Sichuan University. Informed consent was obtained from all subjects.
Detection of AZF structural mutations and Y-chromosome haplogrouping
Genomic DNA was extracted from peripheral blood samples using DNA isolation kits (TaKaRa, Japan). The AZF microdeletion was detected with STS-PCRs (sY84, sY86, sY127, sY134, sY254 and sY255) in 1483 patients with impaired spermatogenesis. For the patients without AZF microdeletion and 1158 controls with normozoospermia, the partial AZFc deletions (gr/gr, b2/b3 and b1/b3 deletion) were analysed with PCRs for sY1291, sY1191 and DYS448. For the subjects with the absence of partial AZFc deletions, copy number analyses of deleted in azoospermia (DAZ), chromodomain Y-linked 1 (CDY1) and basic charge Y-linked 2 (BPY2) were completed with paralogue ratio tests (PRTs) to detect the AZFc duplications (Yang et al., 2015) . The detailed information about the observed AZF structural mutations in the 2641 subjects are shown in Table SI . Then, the Y-chromosome haplogrouping was conducted in the subjects without AZF deletions or duplications. As a result, a total of 1070 men with Y-hg O3 * or O3e defined by M89, M9, M122 and M134 (Jin and Su, 2000) , including 564 men with oligozoospermia and/or asthenozoospermia and 506 men with normozoospermia, were screened for further copy number detection of RBMY1. In addition, the Y-chromosome haplogroups of 486 fertile men were also determined with the four Y-linked markers prior to the detection of the RBMY1 copy number.
RBMY1 CNV detection
For 486 fertile men and 1070 Y-hg O3 * or O3e carriers, the copy dosage of RBMY1 was detected with the AccuCopy ® method (Du et al., 2012) .
Specifically, four RBMY1 functional copy-specific segments were screened as the target of PCR, and four reference segments with constant copy number among individuals were used for normalization (Table SII) . The competitive DNAs for the target and reference segments were designed and synthesized by Genesky Biotechnologies (Shanghai, China). For each sample, a multiplex fluorescence competitive PCR of genomic DNA with the synthesized DNAs was conducted. The PCR products for the genomic and competitive DNAs were separated via capillary electrophoresis (CE) on an ABI 3700XL (Thermo, USA). The calculation of copy dosage and the experimental details have been described in previous reports (Du et al., 2012; Liu et al., 2012) . To explore the potential mechanism underlying the CNV in RBMY1, a group of unique Sequence Tagged Sites (uniSTSs; sY132, sY1315, sY1302, sY1279, sY142, sY3009, sY1258, sY1196, sY1058 and sY1192) located in the flanking sequences of the RBMY1 copy cluster or the intervening sequences between RBMY1 functional copies were detected by PCR in samples with fewer than six copies (Fig. S1 ).
Detection of RBMY1 copy conversion
There is a familiar short tandem repeat (STR) characterized by the tandem repeat of ATAA in intron 2 of all RBMY1 functional copies. Based on the GRCh38/hg38 assembly, RBMY1J, the 3′-end copy in the RBMY1 copy cluster, shows four repeats, and each of the other five upstream copies (RBMY1A1, RBMY1B, RBMY1D, RBMY1E and RBMY1F) presents three repeats (Fig. S1) . A PCR covering this STR was performed, with a product length of 167 bp for RBMY1J and 163 bp for the others (Table SIII) . The copy conversion pattern among the RBMY1 copies was analysed by calculating the ratio of the peak area of the two PCR products, which were separated with CE on an ABI 3700XL. The RBMY1 copy conversion was detected in 1070 men with known spermatogenic condition. 
Quantitative PCR
Western blotting
Total protein was extracted from the sperm collections and testis tissues using a DNA/RNA/Protein Isolation Kit. The protein concentration was measured with a bicinchoninic acid assay (BCA) assay kit (Biotech, China). In the blotting detections, the specific primary antibodies against the proteins, including RBMY1 (Code No.sc-28727, Santa Cruz Biotechnology, USA), glycogen synthase kinase 3β (GSK3β) (Code No. ab32391, Abcam, British), phospho-S9-GSK3β (Code No. ab131097, Abcam, British) and β-actin (Code No. 8H10D10, CST, USA), and the horseradish peroxidaseconjugated secondary antibody were used. The relative amounts of RBMY1, GSK3β and phospho-S9-GSK3β were calculated with β-actin as an internal control.
Sperm swim-up experiment
Eight semen samples were used for the sperm swim-up experiment to separate the sperm with higher motility from those with poorer motility. Semen (1.0 mL) was added into a test tube, overlaid with 2.0 mL of SpermRinse (Vitrolife, Sweden) and placed in an incubator (5% CO 2 ) at 37°C for 60 min. Then, the top medium was transferred into a clean tube, and the sperm with higher motility were collected via centrifugation. The sperm with poorer motility in the bottom semen were separated from the seminal plasma using gradient centrifugation with a gradient solution of SpermRinse and SpermGrad (Vitrolife, Sweden).
Immunofluorescence staining
The sperm from ten semen samples were used for immunofluorescence staining of RBMY1. Sperm smears were fixed with 4% paraformaldehyde in PBS for 15 min, permeabilized with 0.5% Triton X-100 in PBS for 15 min and blocked with 1% bovine serum albumin (BSA) in PBS for 30 min at room temperature. Thereafter, sperm smears were incubated overnight at 4°C with primary antibodies and finally incubated with DyLight 488-or DyLight 594-labelled secondary antibodies (Code No. A21206 & A31570, Life Technologies, USA) for 2 h at room temperature. Each step was followed with three 5 min washes in PBS. Cell nuclei were counterstained with DAPI (Cat. No. D9542, Sigma, USA). The location of RBMY1 in sperm was observed under a laser scanning confocal microscope (Olympus, Japan).
Statistical analysis
Using the SAS 9.4 statistical software (SAS Institute Inc, USA), a multivariable regression analysis was performed to investigate the association of RBMY1 copy dosage or copy conversion with sperm phenotypes. Other statistical analyses were performed with the SPSS 17.0 statistical package (SPSS, USA). An exhaustive Chi-squared automatic interaction detector (CHAID) analysis in the decision tree add-on module was conducted to distinguish RBMY1 copy number range in the groups with normal sperm motility and asthenozoospermia. A Chi-squared test was used to compare RBMY1 copy number (range) distribution among different Y-hgs, between the groups with normozoospermia and oligozoospermia/asthenozoospermia, and between the groups with normal sperm motility and asthenozoospermia. Additionally, it was used to compare the distribution of RBMY1 copy conversion mode between the groups with normal sperm motility and asthenozoospermia. ANOVA was performed to compare sperm motility among males with different RBMY1 copy number ranges and conversion modes. Using the Spearman test, we analysed the correlations between the RBMY1 copy number and sperm motility and its mRNA and protein level. Student's t-test was used to compare sperm motility between the males with six copies and other copy dosages of RBMY1. Using a paired Student's t-test, the difference in RBMY1 protein level between sperm with high and relatively low motility was analysed. Values of P < 0.05 were regarded as statistically significant in all tests except for the multiple comparison tests, for which the degree of significance was corrected using the Bonferroni method. -test for comparing the distribution of the RBMY1 copy number between the groups with NSM and ASZ. The significant level α = 0.05.
Results
Identification of RBMY1 CNV and its distribution characteristics
Using the AccuCopy method, the copy dosage of RBMY1 was detected in 486 fertile men, including 137 with Y-hg O3 * , 125 with Yhg O3e and 224 with other Y-hgs. Our result identified the presence of RBMY1 CNV with ranges from two to ten copies in the population, among which six copies of RBMY1 was the most common dosage and observed in 59.5% of the men (Fig. 1A) . Moreover, a population difference in the distribution of RBMY1 copy number among males with distinct Y-hgs was not detected (χ 2 -test, α = 0.05, P = 0.989) (Fig. 1B) , suggesting that RBMY1 CNV is independent of Y-hg background. This observation indicates that it may not be necessary to consider the influence of the monophyletic group of the Y-chromosome when investigating the association between RBMY1 copy dosage and spermatogenic phenotype.
NAHR-mediated structural rearrangement is a common mechanism underlying the CNV of AZF-linked genes (Jobling, 2008) . However, we did not find the loss of any uniSTSs located in or near the RBMY1 copy cluster in any of the 90 males with fewer than five copies of RBMY1 screened from 486 fertile males. This result suggests that the CNV of RBMY1 may not result from local NAHR and that there may be another mechanism leading to the structural variation.
The effect of RBMY1 CNV on sperm motility
Rbmy1 CNV and sperm phenotypes
We detected RBMY1 copy dosage in 1070 males with Y-hg O3 * or O3e, two common monophyletic groups of the Y-chromosome in the Han Chinese population, including 506 controls with normozoospermia and 564 patients with impaired spermatogenesis (72 men with oligozoospermia, 144 men with asthenozoospermia and 348 men with both defects). The RBMY1 copy number distribution was compared between the two groups and showed a significant population difference (χ 2 -test, α = 0.05, P < 0.001) (Fig. 2) P = 0.020; Y-hg O3e, P = 0.018). Taken together, the results indicate that RBMY1 CNV may be associated with spermatogenic phenotypes.
For each of the main semen parameters, the 1070 men were divided into two groups with the parameters no less than or less than the cut-off value. The cut-off values were 15 million sperm per millilitre for sperm concentration, 39 million for total sperm number, 32% for the percentage of progressively motile sperm and 15.6 million (Pasqualotto et al., 1999; Cooper et al., 2010) for total motile sperm count. Then, using the four main semen phenotypes together as the response variables and the RMBY1 copy dosage as the explanatory variable, incorporating the clinical features (age, body mass index, combined testicular volume, folliclestimulating hormone, luteinizing hormone and testosterone) as covariates, a multivariable regression analysis was performed to identify the sperm phenotype potentially associated with RBMY1 copy dosage. The result indicated that RBMY1 was more likely to be linked to sperm motility (α = 0.05, P = 0.029, OR = 0.70, 95% CI: 0.51-0.98) than sperm product (α = 0.05: sperm concentration, P = 0.783, OR = 0.96, 95% CI: 0.73-1.46; total sperm number, P = 0.819, OR = 1.12, 95% CI: 0.76-1.57; total motile sperm count, P = 0.307, OR = 0.89, 95% CI: 0.62-1.23).
Association of RBMY1 CNV with sperm motility
In this case, we compared the RBMY1 copy number distribution between 578 controls with normal sperm motility (the percentage of progressively motile sperm ≥32%) and 492 patients with asthenozoospermia. The result showed a significant population difference (χ 2 -test, α = 0.05, P < 0.001). The difference was also observed in males with the O3* or O3e Y-hg (χ 2 -test, α = 0.05: Y-hg O3 * , P = 0.009; Y-hg O3e, P = 0.024) ( Table I) . These results support the association between RBMY1 CNV and sperm motility.
To confirm this observation, we further performed an exhaustive CHAID analysis of RBMY1 copy number in the patients and the controls using the Decision Tree add-on module and compared the distribution of RBMY1 copy number ranges (<6, =6 and >6 copies) suggested by CHAID between males with normal sperm motility and asthenozoospermia. The result showed a population difference in the distribution of copy number ranges between the two groups (χ 2 -test, α = 0.05, P = 0.012). As shown in Table II , the difference mainly resulted from the significantly higher proportion of males with fewer than six copies in the group with asthenozoospermia than the group with normal sperm motility (χ 2 -test, α′ = 0.05/2 = 0.025 with Bonferroni correction, P = 0.006). For the males with fewer than six copies of RBMY1, their risk for asthenozoospermia increased by~50% relative to the males with more copies, while such a risk was not observed between the males with more than six copies and those with fewer copies of RBMY1.
The correlation between RBMY1 copy dosage and sperm motility
We further investigated the correlation between the RBMY1 copy dosage and sperm motility characterized by the percentage of progressively motile sperm. A positive correlation was identified in the 1070 subjects (Spearman test, ρ coefficient = 0.129, α = 0.01, P = 0.002).
A similar correlation was also present in 492 patients with asthenozoospermia (ρ coefficient = 0.195, α = 0.01, P < 0.001) and in 578 controls (ρ coefficient = 0.229, α = 0.01, P < 0.001). The above positive correlations were visualized using scatter plots of RBMY1 copy number versus sperm motility (Fig. 3) . Moreover, the mean sperm motility was compared among the three RBMY1 copy number ranges (<6, =6 and >6 copies) in all 1070 males, 578 controls with normal sperm motility and 492 patients with asthenozoospermia. Significant differences were identified (ANOVA, α = 0.05: all males, P = 0.005; controls, P = 0.009; patients, P = 0.019), and males with fewer than six copies of RBMY1 showed lower sperm motility than males with six copies (Student's t-test, α′ = 0.05/2 = 0.025 with Bonferroni correction, all males, P = 0.008; controls, P = 0.010; patients, P = 0.008) ( Table III) . The results further suggest that insufficient RBMY1 copy dosage can lead to decreased sperm motility.
RBMY1 copy conversion with limited effects on sperm motility
To seek more evidence regarding the involvement of RBMY1 in the regulation of sperm motility, we investigated the copy conversion event to analyse its association with sperm phenotypes (Chen et al., 2007; Chuzhanova et al., 2009) . As shown in Fig. 4A-I , a total of two conversion modes characterized by the copy dosage ratios (other copies/RBMY1J) of 5:0 and 3:2 were observed in 146 males with five copies of RBMY1 when taking the most common dosage ratio (4:1) as a reference. Similarly, a conversion mode in 629 males with six copies (4:2) and 184 males with seven copies of RBMY1 (6:1) was found. 
Table III
Comparisons of the sperm motility (mean ± SD) between the groups with six copies of RBMY1 and other copy number ranges in the males with normal sperm motility and asthenozoospermia.
RBMY1 copy number range NSM and ASZ (n = 1070) NSM (n = 578) ASZ (n = 492) Student's t-test for comparing the mean of sperm motility between the groups with six copies and other copy number ranges. The significant level α′ = 0.05/2 = 0.025 with Bonferroni correction. Figure 4 Investigation of the copy conversion of RBMY1 and its association with sperm motility. NSM, normal sperm motility; ASZ, asthenozoospermia. (A) Seven males with two RBMY1 copies. Only the copy dosage ratio of 0:2 (other copies/RBMY1J) was observed by calculating the ratio of the peak area of two fragments (163 bp and 167 bp). (B) Sixteen males with three RBMY1 copies. Only the copy dosage ratio of 2:1 was observed.
(C) Forty-two males with four RBMY1 copies. Only the copy dosage ratio of 3:1 was observed. (D) One hundred forty-six males with five RBMY1 copies. A total of three copy dosage ratios, including 4:1 (n = 116) (D1), 3:2 (n = 26) (D2) and 5:0 (n = 4) (D3), were observed. (E) Six hundred twentynine males with six RBMY1 copies. Two copy dosage ratios, 5:1 (n = 394) (E1) and 4:2 (n = 235) (E2), were observed. (F) One hundred eighty-four males with seven RBMY1 copies. Two copy dosage ratios, 5:2 (n = 134) (F1) and 6:1 (n = 50) (F2), were observed. (G) Thirty-one males with eight RBMY1 copies. Only the copy dosage ratio of 6:2 was observed. (H) Eleven males with nine RBMY1 copies. Only the copy dosage ratio of 7:2 was observed. (I) Four males with ten RBMY1 copies. Only the copy dosage ratio of 8:2 was observed. (J-L) Comparison of the distributions of the copy dosage ratios between the groups with ASZ and NSM in males with the same copy dosage. A distribution difference was not observed in the groups with five (J), six (K) or seven copies (L) of RBMY1 (χ These observations suggest that RBMY1 presents frequent copy conversion in its copy cluster. However, three multivariable regression analyses with clinical features as covariates in groups with total five, six or seven copies of RBMY1 did not show any significant association of the RBMY1 copy dosage ratios with sperm motility in males with the same dosage of functional RBMY1 (α = 0.05; total five copies, P = 0.731; total six copies, P = 0.836; total seven copies, P = 0.755). Moreover, the distributions of the RBMY1 copy dosage ratios did not differ between the group with normal sperm motility and the group with asthenozoospermia (Fig. 4J-L) , and there was not any differences in the mean sperm motility among or between the groups with different copy dosage ratios (Table SIV) . Briefly, the observations did not provide additional evidence of the effect of RBMY1 on sperm motility, which may be due to the fact that the different RBMY1 copies possess similar functions. Ultimately, the sequence similarity of their open reading frames reaches 99.7% according to the reference sequence of the GRCh38/ hg38 assembly.
A positive correlation between RBMY1 copy dosage and its mRNA and protein levels in testis
The qualification of RBMY1 copy number and its mRNA and protein levels in 15 testicular tissues was performed with Accucopy PCR, qPCR and western blot. Positive correlations were observed between RBMY1 dosage and RBMY1 mRNA level (Spearman test, ρ coefficient = 0.791, α = 0.05, P = 0.024) and protein level (Spearman test, ρ coefficient = 0.722, α = 0.05, P = 0.033) in testis (Fig. 5) .
A relationship between the amount of RBMY1 protein in sperm and sperm motility For each of the semen samples from eight males, we detected the amount of RBMY1 protein in sperm with high and relatively low motility separated by the sperm swim-up technique by western blot. The result indicated that the sperm with high motility carried more RBMY1 protein than those with low motility (Paired Student's t-test, α = 0.05, P < 0.001) (Fig. 6A and B) . However, in the same semen samples we did not observe a difference in the level of phospho-S9-GSK3β protein between the sperm with high and low motility, although the amount of GSK3β protein was similar between the two types of sperm (Fig. S2) .
Location of the RBMY1 protein in sperm
Immunofluorescence staining of sperm was performed to investigate the subcellular location of the RBMY1 protein. The RBMY1 protein was located mainly in the neck and mid-piece region of sperm as well as the principal piece of the sperm tail (Fig. 7) . and its mRNA and protein levels in the testis. The RBMY1 copy dosage of each sample was shown in the bracket after its serial number. The relative quantity of RBMY1 copy dosage and its mRNA and protein levels of the samples was obtained by comparing the measurements with those of the first sample (T1) and the latter's were used as controls by setting to one arbitrary unit. A positive correlation was observed between RBMY1 dosage and its mRNA level (Spearman test, ρ coefficient = 0.791, α = 0.05, P = 0.024) as well as its protein level (Spearman test, ρ coefficient = 0.722, α = 0.05, P = 0.033).
Discussion
The RBMY1 gene encodes an RNA-binding protein exclusively expressed in adult testis that is involved in controlling transcription in the developmental processes of germ cells by acting as an inhibitor of mRNA splicing activity. Elliott, 2000; Venables et al., 2000; Skrisovska et al., 2007; Dreumont et al., 2010) . Recently, a detailed study of mammalian Y-chromosomes has revealed that the ancestral Y-linked genes related to spermatogenesis exhibit a copyamplifying trend and that their expression was gradually restricted to the testis through evolution (Bellott et al., 2014) . Taken together, the findings provide evidence that RBMY1 contributes to spermatogenesis. However, our knowledge regarding its physiological and pathological characters in terms of spermatogenic phenotypes is greatly limited.
RBMY1 CNV was observed in 411 healthy UK males. As discussed in that report, however, that copy number analysis did not distinguish functional copies from RBMY1 pseudogenes (Wei et al., 2015) . In the present study, we focused on quantification of the AZFb-linked RBMY1 functional copies by using four detection targets specific for the copies. With this work, continuous copy dosage was observed, with a range from two to ten in 486 fertile males and 1070 males with known spermatogenic condition; nearly 60% of the males carried six RBMY1 copies. These findings are the first to identify Y-hg-independent number variation in the functional RBMY1 copy.
Interestingly, further population investigation showed a significant association of RBMY1 CNV with sperm motility rather than sperm product, which is most likely related to the known function of RBMY1 as a regulator of pre-mRNA splicing. Our study identified a positive correlation between RBMY1 copy dosage and sperm motility characterized by the percentage of progressively motile sperm, an important sperm phenotype reflecting male reproductive function. In fact, an increased risk for asthenozoospermia in males with copy dosageinsufficiency of RBMY1 (<6 copies) suggests the importance of RBMY1 in maintaining the sperm motility required for male reproduction and the contribution of this gene to male infertility. To the best of our knowledge, this is the first time that an AZF-linked gene has been shown to have an independent effect on sperm motility in a population study. The finding enriches our understanding of the function of the AZF region but requires further confirmation in more populations.
It has previously been suggested that the function of the RBMY1 protein may be involved in sperm motility. Important evidence of this is the finding that sperm treated with RBMY1 antibodies showed decreased motility (Abid et al., 2013) . In the present study, we provided further support for this, including the positive correlations between RBMY1 dosage and mRNA and protein levels in testis tissue and between sperm RBMY1 protein level and motility. These findings, together with the observations in the population study, complete an evidence chain that strongly suggests the involvement of RBMY1 in the regulation of sperm motility. However, it is obvious that the effect of RBMY1 on the motility of ejaculated spermatozoa cannot be well explained with the known function of the protein, since the genetic expression as a whole is silenced in spermatozoa.
The sperm flagellar beat has a crucial role in sperm motility and is primarily regulated by Ca 2+ signalling (Suarez, 2008; Darszon et al., 2011) . Increases in cytoplasmic Ca 2+ concentration, as a result of the opening of Ca 2+ channels in the plasma membrane and/or the release of Ca 2+ from intracellular stores, can lead to the hyperactivation of sperm (Ho and Suarez, 2001; Carlson et al., 2005; Jimenez-Gonzalez et al., 2006; Suarez, 2008) . Similar to the finding in a previous study (Abid et al., 2013) , we also observed the concentration of RBMY1 in the mid-piece region of sperm and the principal piece of the sperm tail, which contains several Ca 2+ channels and pumps involved in sperm hyperactivation (Olson et al., 2011) , including two primary sperm plasma membrane Ca 2+ channels, CatSper channels and plasma membrane Ca 2+ ATPase (Okunade et al., 2004; Kirichok et al., 2006) .
In addition, we observed the presence of RBMY1 in the neck of sperm, where the redundant nuclear envelope contains an IP3-gated Ca 2+ Figure 7 Location of the RBMY1 protein in sperm. The RBMY1 protein (green fluorescence) was mainly present in the neck and mid-piece region of sperm as well as the principal piece of the sperm tail. The β-actin protein (red fluorescence) was only present in sperm tail. Sperm nucleus was counterstained blue with DAPI. Scale bar: 20 μm.
store as a source of Ca 2+ for the hyperactivation of sperm (Ho and Suarez, 2003) . In this case, it is possible that RBMY1 may regulate sperm motility by influencing the function of Ca 2+ channels or stores to support sperm hyperactivation. Moreover, a recent study has revealed that RBMY1 inhibits the function of GSK3β by binding to GSK3β and catalysing its phosphorylation inactivation (Chua et al., 2015) . The influence of GSK3β activity on sperm motility has been observed and discussed for nearly 20 years (Vijayaraghavan et al., 1996 (Vijayaraghavan et al., , 2000 Smith et al., 1999; Somanath et al., 2004) , and a negative correlation between phospho-S9-GSK3β and the motility of human ejaculated spermatozoa was recently identified (Silva et al., 2015) . Reasonably, these findings imply that there may be a potential GSK3β-related mechanism underlying the RBMY1-mediated regulation of sperm motility. However, in the present study, we did not obtain evidence for the involvement of phospho-S9-GSK3β in RBMY1 function on sperm motility. Greater effort should be paid to clarify the issue in a future study.
In conclusion, the present study first identified variation in the number of functional RBMY1 copies. Our results strongly suggest that RBMY1, as an independent genetic factor, is involved in the regulation of sperm motility and influences the susceptibility of males to asthenozoospermia. This study suggests that genetic analysis of the RBMY1 copy number could inform the clinical counselling of male infertility.
Supplementary data
Supplementary data are available at Human Reproduction online.
